WE DEVELOP AN ANTI-INFLAMMATORY DRUG WITH FIRST-IN-CLASS POTENTIAL
We aim to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions.
Lipum also address the treatment of Juvenile Iodiopathic Artrithis (JIA) that is a rare disease affecting children. A novel biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.
Our biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.
LENNART LUNDBERG JOINS LIPUM´S SCIENTIFIC ADVISORY BOARD
Lennart Lundberg is a Professor of Protein Biotechnology with more than 30 years’ experience in the pharmaceutical and biotechnology industries. He is one of the three founders that started Lipum AB (PLC) in 2010 and has since been on the board as both Chairman and member.
GROWING UP WITH JUVENILE IDIOPATHIC ARTHRITIS
Every year more than 200 Swedish children are diagnosed with juvenile idiopathic arthritis (JIA), also known as childhood arthritis, a rheumatic disease that affects the joints and can cause severe pain. For those affected the disease can cause considerable suffering and result in a reduced quality of life. To gain a greater understanding of how JIA affects young people we have spoked with Clara Laurell, who has lived with the disease for several years.
NEWS
Lipum initiates collaboration with Pelago Bioscience
News: Umeå, 13 May 2022. Lipum AB (publ) has started a collaboration with Pelago Bioscience AB to strengthen the bioanalytical development for pre-clinical and clinical…
Biostock: RA patients in great need of new treatment options
Following the FDA’s safety warnings, a shift is seen away from JAK inhibitors for the treatment of rheumatoid arthritis. The changes in the market, and…
Lipum abstract accepted for EULAR 2022
News: Umeå, 7 April 2022. Lipum (publ) reports that the abstract entitled “A Novel Target for Treatment of Inflammatory Joint Diseases” has been selected for…
PRESS RELEASES
Lipum AB – interim report for the period January-March 2022
Press release: Umeå, 18 May 2022. Lipum AB (publ) has published the interim report for period January to March for 2022. Below is a summary,…
Lipum in consortium being granted research funding by KKS
Press release: Umeå, 5 May 2022. Lipum AB (publ) is one of the partners contributing to the KKS-Synergy grant application “Drug discovery targeting inflammation –…
Lipum AB – Year-end report 2021
Press release: Umeå, 25 March 2022. Lipum AB (publ) has published the interim report for period October to December and the year-end report for 2021.…